Few studies evaluated patient-reported outcomes (PROs) for patients with hematologic
malignancies receiving with Chimeric Antigen Receptor T (CAR-T) cell therapy. We …

The inclusion of patient-reported outcome (PRO) measures in chimeric antigen receptor
(CAR) T-cell therapy research is critical for understanding the impact of this novel approach …

Chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment for
relapsed/refractory hematologic malignancies; however, data on patient-reported outcomes …

The success of chimeric antigen receptor (CAR) T cell therapy in treating patients with
relapsed/refractory hematologic malignancies is leading to a growing number of survivors …

Background: Chimeric Antigen-Receptor-T-cell (CAR-T) therapy is a potentially life-saving
treatment for refractory haematological malignancies. Internationally, CAR-T services are …

Abstract Purpose of Review Chimeric antigen receptor (CAR) T-cell therapy is a relatively
new, innovative treatment strategy to manage refractory hematological cancers, including …

Introduction Adoptive cell therapy (ACT) is a rapidly evolving field. Patient-reported
outcomes (PROs) allow patients to report the impact of treatment on their quality of life …

Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of patients with
relapsed/refractory B-cell-derived hematologic malignancies. To date, six CAR T-cell …

Chimeric antigen receptor (CAR) T-cell therapy is associated with potentially severe
toxicities that create a substantial burden for patients. Patient-reported outcomes (PROs) …

For the reasons listed above, standardised, comprehensive supportive care is critically
important to ensure that CAR-T therapy is delivered as safely as possible and that patients …